These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2468049)

  • 1. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers.
    Ishizaki T; Baba T; Murabayashi S; Kubota K; Hara K; Kurimoto F
    J Cardiovasc Pharmacol; 1988; 12(5):512-9. PubMed ID: 2468049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics and dynamics of enalapril in patients with liver cirrhosis.
    Ohnishi A; Tsuboi Y; Ishizaki T; Kubota K; Ohno T; Yoshida H; Kanezaki A; Tanaka T
    Clin Pharmacol Ther; 1989 Jun; 45(6):657-65. PubMed ID: 2543535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
    Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
    J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short term effects of acute inhibition of the angiotensin-converting enzyme on the renin-angiotensin system and plasma atrial natriuretic peptide in healthy dogs fed a low-sodium diet versus a normal-sodium diet.
    Koch J; Pedersen HD; Jensen AL; Flagstad A; Poulsen K; Bie P
    Zentralbl Veterinarmed A; 1994 Mar; 41(2):121-7. PubMed ID: 8091887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients].
    Gotoh M; Mizuno K; Hashimoto S; Kunii N; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1985 May; 61(5):619-29. PubMed ID: 2991035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
    Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
    Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Ajayi AA; Hockings N; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):349-57. PubMed ID: 3011047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study.
    Chalmers JP; Wing LM; West MJ; Bune AJ; Elliott JM; Morris MJ; Cain MD; Graham JR; Southgate DO
    Aust N Z J Med; 1986 Aug; 16(4):475-80. PubMed ID: 3026294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects.
    Weisser K; Schloos J; Lehmann K; Düsing R; Vetter H; Mutschler E
    Eur J Clin Pharmacol; 1991; 40(1):95-9. PubMed ID: 1647954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach.
    Ribeiro W; Muscará MN; Martins AR; Moreno H; Mendes GB; de Nucci G
    Eur J Clin Pharmacol; 1996; 50(5):399-405. PubMed ID: 8839663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
    Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
    Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.
    McIntyre M; MacFadyen RJ; Meredith PA; Menard J; Brunner HR; Insuasty J; Reid JL
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):994-1000. PubMed ID: 7564347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.
    Edeki T; Johnston A; Li Kam Wa E; Turner P
    Int J Clin Pharmacol Ther; 1994 Mar; 32(3):142-6. PubMed ID: 8205376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension.
    Donnelly R; Elliott HL; Meredith PA; Reid JL
    J Cardiovasc Pharmacol; 1987 Dec; 10(6):723-7. PubMed ID: 2450244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
    Jackson B; Cubela R; Johnston CI
    J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition.
    Ripley EB; Gehr TW; Kish CW; Sica DA
    Perit Dial Int; 1994; 14(4):378-83. PubMed ID: 7827189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of enalapril, a new converting enzyme inhibitor, in hypertension.
    Ferguson RK; Vlasses PH; Swanson BN; Mojaverian P; Hichens M; Irvin JD; Huber PB
    Clin Pharmacol Ther; 1982 Jul; 32(1):48-53. PubMed ID: 6282527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
    Lantis AC; Ames MK; Werre S; Atkins CE
    J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and adrenal resistance against atrial natriuretic peptide in congestive heart failure: effect of angiotensin I-converting-enzyme inhibition.
    Wambach G; Schittenhelm U; Bönner G; Kaufmann W
    Cardiology; 1989; 76(6):418-27. PubMed ID: 2558792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.